The PRESERVE Study continues to add to the growing body of evidence supporting the NanoKnife System for prostate tissue ablation.
The PRESERVE Study, the first Society of Urologic Oncology-sponsored trial in focal therapy, is complete and results are published.1 Building on this foundation, the PRESERVE Trial continues to evaluate long-term outcomes with focal irreversible electroporation (IRE) using the NanoKnife System in intermediate-risk prostate cancer.
Recently released 24-month data2 demonstrated durable oncologic outcomes, sustained safety findings, and strong patient follow-up across a multi-center U.S. study conducted in collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).
